AstraZeneca Earnings Date, Estimates, & History

+0.74 (+1.26 %)
(As of 09/23/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume5.32 million shs
Average Volume9.89 million shs
Market Capitalization$184.28 billion
P/E Ratio41.31
Dividend Yield2.33%

Earnings Summary

Earnings Date
Nov. 4

Actual EPS
(Jul. 28)
Beat By $0.02

Consensus EPS
(Jul. 28)

Last Year's Q3 EPS

AstraZeneca Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

AstraZeneca Estimated Revenue and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

AstraZeneca (NASDAQ:AZN) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20212$0.59$0.72$0.66 
Q2 20212$0.44$0.46$0.45 
Q3 20212$0.64$0.68$0.66 
Q4 20212$0.67$0.79$0.73 
FY 20218$2.34$2.65$2.50

AZN Earnings Information

AstraZeneca last posted its quarterly earnings data on July 28th, 2021. The reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.02. The company earned $8.22 billion during the quarter, compared to the consensus estimate of $7.79 billion. AstraZeneca has generated $2.01 earnings per share over the last year ($1.44 diluted earnings per share) and currently has a price-to-earnings ratio of 41.3. Earnings for AstraZeneca are expected to grow by 34.09% in the coming year, from $2.64 to $3.54 per share. AstraZeneca has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 4th, 2021 based off prior year's report dates.

AstraZeneca (NASDAQ:AZN) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
7/28/20216/30/2021$0.43$0.45+$0.02$0.69$7.79 billion$8.22 billion    
4/29/20213/31/2021$0.71$0.82+$0.11$1.03$7.15 billion$7.32 billion  
2/10/202112/31/2020$0.68$0.54($0.14)$0.69$6.98 billion$7.41 billion  
11/10/20209/30/2020$0.44$0.47+$0.03$0.69$6.65 billion$6.58 billion  
11/5/2020Q3 2020$0.49$0.47($0.02)$0.69$6.54 billion$6.58 billion
7/30/2020Q2 2020$0.44$0.48+$0.04$0.67$6.25 billion$6.28 billion
7/30/20206/30/2020$0.44$0.48+$0.04$0.67$6.27 billion$6.28 billion  
4/29/2020Q1 2020$0.47$0.53+$0.06$0.76$5.81 billion$6.35 billion
4/29/20203/31/2020$0.47$0.53+$0.06$0.76$5.95 billion$6.35 billion  
2/14/2020Q4 2019$0.53$0.45($0.08)$0.78$6.71 billion$6.66 billion
2/14/202012/31/2019$0.53$0.45($0.08)$0.78$6.75 billion$6.66 billion  
10/24/2019Q3 2019$0.45$0.50+$0.05$0.88$6.14 billion$6.41 billion
10/24/20199/30/2019$0.45$0.50+$0.05$0.88$6.07 billion$6.13 billion  
7/25/2019Q2 2019$0.32$0.37+$0.05$0.69$5.51 billion$5.82 billion
7/25/20196/30/2019$0.30$0.73+$0.43$1.37$5.57 billion$5.72 billion  
4/26/2019Q1 2019$0.43$0.45+$0.02$0.66$5.27 billion$5.49 billion
4/26/20193/31/2019$0.43$0.45+$0.02$0.66$5.40 billion$5.47 billion  
2/14/2019Q4 2018$0.73$0.79+$0.06$1.17$6.16 billion$6.42 billion
2/14/201912/31/2018$0.73$1.58+$0.85$2.34$6.33 billion$6.42 billion  
11/8/2018Q3 2018$0.33$0.36+$0.03$0.55$5.12 billion$5.34 billion
11/8/20189/30/2018$0.33$0.71+$0.38$1.08$5.26 billion$5.34 billion  
7/26/2018Q2 2018$0.31$0.35+$0.04$0.56$4.99 billion$5.16 billion
7/26/20186/30/2018$0.31$0.69+$0.38$1.11$5.09 billion$5.16 billion  
5/18/2018Q1 2018$0.28$0.24($0.04)$0.35$5.34 billion$5.18 billion
5/18/20183/31/2018$0.28$0.48+$0.20$0.69$5.24 billion$5.18 billion  
2/2/2018Q4 2017$0.45$0.65+$0.20$0.78$5.59 billion$5.78 billion
2/2/2018Q4 2017$0.44$1.30+$0.86$1.57$5.49 billion$5.78 billion  
11/9/2017Q3 2017$0.57$0.56($0.01)$0.85$5.75 billion$6.23 billion
11/9/2017Q3$0.57$1.12+$0.55$1.70$6.00 billion$6.23 billion
7/27/2017Q2 2017$0.41$0.44+$0.03$0.69$5.05 billion$5.05 billion
7/27/20176/30/2017$0.41$0.87+$0.46$1.36$5.04 billion$5.05 billion
4/27/2017Q1 2017$0.38$0.50+$0.12$0.79$5.41 billion$5.41 billion
4/27/20173/31/2017$0.38$0.99+$0.61$1.56$5.40 billion$5.41 billion
2/2/2017Q4 2016$0.51$0.61+$0.10$0.49$5.61 billion$5.59 billion
2/2/2017Q416$0.51$1.21+$0.70$0.97$5.43 billion$5.59 billion  
11/10/2016Q3 2016$0.48$0.66+$0.18$0.92$5.95 billion$5.70 billion
11/10/2016Q316$0.48$1.32+$0.84$1.84$5.95 billion$5.70 billion
7/28/2016Q2 2016$0.42$0.42$0.84$5.58 billion$5.60 billion
7/28/2016Q216$0.76$0.83+$0.07$1.66$5.56 billion$5.60 billion  
4/29/2016Q1 2016$0.60$0.48($0.12)$0.70$5.90 billion$6.12 billion
4/29/2016Q1$0.5970$0.51($0.0870)$1.39$5.96 billion$6.12 billion  
2/4/2016Q4 2015$0.88$0.47($0.41)$0.62$6.19 billion$6.40 billion
2/4/2016Q415$0.88$0.94+$0.06$1.26$6.27 billion$6.40 billion
11/5/2015Q3 2015$0.51$0.51$0.72$5.93 billion$5.95 billion
11/5/2015Q315$0.51$1.03+$0.52$1.45$5.90 billion$5.85 billion
7/30/2015Q2 2015$0.52$0.61+$0.09$0.94$6.10 billion$6.31 billion
7/30/2015Q2$0.52$1.21+$0.69$1.87$6.02 billion$5.84 billion  
4/24/2015Q1 2015$0.54$0.54$0.86$5.93 billion$6.06 billion
4/24/2015Q1$1.07$1.08+$0.01$0.86$5.87 billion$6.06 billion
2/5/2015Q4 2014$0.42$0.38($0.04)$0.89$6.70 billion$6.68 billion
2/5/2015Q314$0.85$0.76($0.09)$0.89$6.68 billion$6.68 billion
11/6/2014Q3 2014$0.52$0.53+$0.01$0.96$6.35 billion$6.54 billion
11/6/2014Q3$1.04$1.05+$0.01$0.96$6.44 billion$6.54 billion
7/31/2014Q2 2014$0.57$0.65+$0.08$0.98$6.18 billion$6.45 billion
7/31/2014Q214$1.09$1.30+$0.21$0.98$6.24 billion$6.45 billion  
4/29/2014Q1 2014$0.60$0.59($0.01)$0.98$6.28 billion$6.42 billion
4/29/2014Q114$1.23$1.17($0.06)$0.98$6.32 billion$6.42 billion  
2/6/2014Q4 2013$0.64$0.62($0.02)$1.45$6.94 billion$6.84 billion
2/6/2014Q4 2013$0.64$0.62($0.02)$1.45$6.91 billion$3.84 billion
10/31/2013Q3 2013$0.64$0.61($0.03)$0.72$6.45 billion$6.25 billion
10/31/2013Q3 2013$0.64$0.61($0.03)$0.72$6.45 billion$6.25 billion  
8/1/2013Q2 2013$0.59$0.60+$0.01$0.87$6.24 billion$6.23 billion
8/1/2013Q2 2013$0.59$0.60+$0.01$0.87$6.24 billion$6.23 billion  
4/25/2013Q1 2013$0.67$0.71+$0.04$1.01$6.50 billion$6.39 billion
4/25/2013Q1 2013$0.67$0.71+$0.04$1.01$6.54 billion$6.39 billion  
1/31/2013Q412$1.37$1.56+$0.19$7.17 billion$7.28 billion  
4/27/2011Q1 2011$1.02$1.04+$0.02$1.04
1/27/2011Q4 2010$0.67$0.68+$0.01$0.79
10/27/2010Q3 2010$0.76$0.54($0.22)$0.54
7/30/2010Q2 2010$0.80$0.73($0.07)$0.73
4/29/2010Q1 2010$0.86$1.02+$0.16$1.08
10/29/2009Q3 2009$0.68$0.73+$0.05$0.73
7/30/2009Q2 2009$0.68$0.82+$0.14$1.05
1/29/2009Q4 2008$0.59$0.63+$0.04$0.83
4/24/2008Q1 2008$0.60$0.52($0.08)$0.52
1/31/2008Q4 2007$0.50$0.52+$0.02$0.61
(Earnings results data provided by Zacks Investment Research)
speech bubbles
speech bubbles

AstraZeneca (NASDAQ:AZN) Earnings Frequently Asked Questions

When is AstraZeneca's earnings date?

AstraZeneca has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 4th, 2021 based off last year's report dates. Learn more on AZN's earnings history

Did AstraZeneca beat their earnings estimates last quarter?

In the previous quarter, AstraZeneca (NASDAQ:AZN) reported $0.45 earnings per share (EPS) to beat the analysts' consensus estimate of $0.43 by $0.02. Learn more on AZN's earnings details

How can I listen to AstraZeneca's earnings conference call?

The conference call for AstraZeneca's latest earnings report can be listened to online. Listen to Conference Call

How can I read AstraZeneca's conference call transcript?

The conference call transcript for AstraZeneca's latest earnings report can be read online. Read Transcript

How much revenue does AstraZeneca generate each year?

AstraZeneca (NASDAQ:AZN) has a recorded annual revenue of $26.62 billion.

How much profit does AstraZeneca generate each year?

AstraZeneca (NASDAQ:AZN) has a recorded net income of $3.20 billion. AZN has generated $2.01 earnings per share over the last four quarters.

What is AstraZeneca's price-to-earnings ratio?

AstraZeneca (NASDAQ:AZN) has a trailing price-to-earnings ratio of 41.31 and a forward price-to-earnings ratio of 22.53. The price/earnings-to-growth ratio is 1.21.

What is AstraZeneca's EPS forecast for next year?

AstraZeneca's earnings are expected to grow from $2.64 per share to $3.54 per share in the next year, which is a 34.09% increase.

This page was last updated on 9/24/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.